Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus

References

• KannelWBMcGeeDLDiabetes and cardiovascular risk factors: the Framingham studyCirculation1979591813758126
   PubMed Web of Science ®Google Scholar
• AronsonDRayfieldEJHow hyperglycemia promotes atherosclerosis: molecular mechanismsCardiovasc Diabetol20021112119059
   PubMed Web of Science ®Google Scholar
• BaysHE“Sick fat,” metabolic disease, and atherosclerosisAm J Med2009122Suppl 1S26S3719110085
   PubMed Web of Science ®Google Scholar
• BaysHEAdiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating “sick fat” through improving fat function with antidiabetes therapiesAm J Cardiol2012110Suppl 94B12B
   Web of Science ®Google Scholar
• RayKKSeshasaiSRWijesuriyaSEffect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trialsLancet200937396771765177219465231
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes – 2013Diabetes Care201336 Suppl 1S11S6623264422
   PubMed Web of Science ®Google Scholar
• GrundySMCleemanJIMerzCNNational Heart, Lung, and Blood InstituteAmerican College of Cardiology FoundationAmerican Heart AssociationImplications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelinesCirculation2004110222723915249516
   PubMed Web of Science ®Google Scholar
• JellingerPSSmithDAMehtaAEAACE Task Force for Management of Dyslipidemia and Prevention of AtherosclerosisAmerican Association of Clinical Endocrinologists’ Guidelines for Management of Dyslipidemia and Prevention of AtherosclerosisEndocr Pract201218Suppl 117822522068
   PubMedGoogle Scholar
• StoneNJRobinsonJLichtensteinAH2013ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesCirculation Epub11122013
   Google Scholar
• CheungBMOngKLChernySSShamPCTsoAWLamKSDiabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006Am J Med2009122544345319375554
   PubMed Web of Science ®Google Scholar
• BerneCSiewert-DelleAURANUS study investigatorsComparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS studyCardiovasc Diabetol20054715935095
   PubMed Web of Science ®Google Scholar
• GargAGrundySMLovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitusN Engl J Med1988318281863422105
   PubMed Web of Science ®Google Scholar
• KnoppRHFrohlichJJokubaitisLADawsonKBroylesFEGomez-CoronadoDEfficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemiaAm J Med1994966A69S78S8017470
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) CollaboratorsKearneyPMBlackwellLEfficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysisLancet2008371960711712518191683
   PubMed Web of Science ®Google Scholar
• DavidsonMHMakiKCPearsonTAResults of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendationsAm J Cardiol200596455656316098311
   PubMed Web of Science ®Google Scholar
• NichollsSJBrandrup-WognsenGPalmerMBarterPJMeta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER)Am J Cardiol20101051697620102893
   PubMed Web of Science ®Google Scholar
• SilvaMMatthewsMLJarvisCMeta-analysis of drug-induced adverse events associated with intensive-dose statin therapyClin Ther200729225326017472818
   PubMed Web of Science ®Google Scholar
• PreissDSeshasaiSRWelshPRisk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysisJAMA2011305242556256421693744
   PubMed Web of Science ®Google Scholar
• RautioNJokelainenJOksaHDo statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D projectBMJ Open201225
   Web of Science ®Google Scholar
• SattarNPreissDMurrayHMStatins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsLancet2010375971673574220167359
   PubMed Web of Science ®Google Scholar
• ZaharanNLWilliamsDBennettKStatins and risk of treated incident diabetes in a primary care populationBr J Clin Pharmacol20137541118112422845189
   PubMed Web of Science ®Google Scholar
• HandelsmanYMechanickJIBlondeLAACE Task Force for Developing Diabetes Comprehensive Care PlanAmerican Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care planEndocr Pract201117Suppl 215321474420
   PubMed Web of Science ®Google Scholar
• [No authors listed]Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert PanelArch Intern Med1988148136693422148
   PubMed Web of Science ®Google Scholar
• [No authors listed]The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol loweringJAMA198425133653746361300
   PubMed Web of Science ®Google Scholar
• AndradeSEWalkerAMGottliebLKDiscontinuation of antihyperlipidemic drugs – do rates reported in clinical trials reflect rates in primary care settings?N Engl J Med199533217112511317700285
   PubMed Web of Science ®Google Scholar
• AvornJMonetteJLacourAPersistence of use of lipid-lowering medications: a cross-national studyJAMA199827918145814629600480
   PubMed Web of Science ®Google Scholar
• FlorentinMLiberopoulosENMikhailidisDPElisafMSColesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemiaCurr Med Res Opin2008244995100918291066
   PubMed Web of Science ®Google Scholar
• WELCHOL^® (colesevelam hydrochloride) [prescribing information]Daiichi Sankyo IncParsippany, NJ2014 [revised Jan 2014]
   Google Scholar
• GoodwinBJonesSAPriceRRA regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesisMol Cell20006351752611030332
   PubMed Web of Science ®Google Scholar
• LefebvrePCariouBLienFKuipersFStaelsBRole of bile acids and bile acid receptors in metabolic regulationPhysiol Rev200989114719119126757
   PubMed Web of Science ®Google Scholar
• StaelsBA review of bile acid sequestrants: potential mechanism(s) for glucose-lowering effects in type 2 diabetes mellitusPostgrad Med20091213 Suppl 1253019494475
   PubMed Web of Science ®Google Scholar
• BaysHEGoldbergRBThe ‘forgotten’ bile acid sequestrants: is now a good time to remember?Am J Ther200714656758018090882
   PubMedGoogle Scholar
• PotthoffMJPottsAHeTColesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO miceAm J Physiol Gastrointest Liver Physiol20133044G371G38023257920
   PubMed Web of Science ®Google Scholar
• GargAGrundySMCholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trialAnn Intern Med199412164164228053615
   PubMed Web of Science ®Google Scholar
• BaysHEGoldbergRBTruittKEJonesMRColesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effectsArch Intern Med2008168181975198318852398
   PubMedGoogle Scholar
• FonsecaVARosenstockJWangACTruittKEJonesMRColesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapyDiabetes Care20083181479148418458145
   PubMed Web of Science ®Google Scholar
• GoldbergRBFonsecaVATruittKEJonesMREfficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapyArch Intern Med2008168141531154018663165
   PubMedGoogle Scholar
• JialalIAbbySLMisirSNagendranSConcomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: a pooled analysisMetab Syndr Relat Disord20097325525819344229
   PubMedGoogle Scholar
• YamakawaTTakanoTUtsunomiyaHKadonosonoKOkamuraAEffect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemiaEndocr J2007541535817102570
   PubMed Web of Science ®Google Scholar
• CaoGLiangYBroderickCLAntidiabetic action of a liver X receptor agonist mediated by inhibition of hepatic gluconeogenesisJ Biol Chem200327821131113612414791
   PubMed Web of Science ®Google Scholar
• LaffitteBAChaoLCLiJActivation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissueProc Natl Acad Sci U S A200310095419542412697904
   PubMed Web of Science ®Google Scholar
• BaranowskiMBiological role of liver X receptorsJ Physiol Pharmacol200859 Suppl 7315519258656
   PubMed Web of Science ®Google Scholar
• GoldfineABModulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathwayCurr Opin Cardiol200823550251118670263
   PubMed Web of Science ®Google Scholar
• ReasnerCAReducing cardiovascular complications of type 2 diabetes by targeting multiple risk factorsJ Cardiovasc Pharmacol200852213614418670366
   PubMed Web of Science ®Google Scholar
• StaelsBHandelsmanYFonsecaVBile acid sequestrants for lipid and glucose controlCurr Diab Rep2010101707720425070
   PubMed Web of Science ®Google Scholar
• PotthoffMJBoney-MontoyaJChoiMFGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathwayCell Metab201113672973821641554
   PubMed Web of Science ®Google Scholar
• EfanovAMSewingSBokvistKGromadaJLiver X receptor activation stimulates insulin secretion via modulation of glucose and lipid metabolism in pancreatic beta-cellsDiabetes200453 Suppl 3S75S7815561926
   PubMed Web of Science ®Google Scholar
• HarachTPolsTWNomuraMTGR5 potentiates GLP-1 secretion in response to anionic exchange resinsSci Rep2012243022666533
   PubMed Web of Science ®Google Scholar
• JonesMBaysHColesevelam HCl: glycemic and lipid parameter effects in patients with type 2 diabetes mellitus treated with metformin-based therapy and a statinPaper presented at: AACE 21st Annual Scientific and Clinical CongressMay 23–27, 2012Philadelphia, PA
   Google Scholar
• GoldenbergIBenderlyMGoldbourtUUpdate on the use of fibrates: focus on bezafibrateVasc Health Risk Manag20084113114118629356
   PubMedGoogle Scholar
• MooradianADDyslipidemia in type 2 diabetes mellitusNat Clin Pract Endocrinol Metab20095315015919229235
   PubMedGoogle Scholar
• [No authors listed]Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised studyLancet2001357926090591011289345
   PubMed Web of Science ®Google Scholar
• KeechASimesRJBarterPFIELD study investigatorsEffects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialLancet200536695001849186116310551
   PubMed Web of Science ®Google Scholar
• ACCORD Study GroupGinsbergHNElamMBEffects of combination lipid therapy in type 2 diabetes mellitusN Engl J Med2010362171563157420228404
   PubMed Web of Science ®Google Scholar
• BaysHERothEMMcKenneyJMThe effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemiaDiabetes Care20103392113211620573750
   PubMed Web of Science ®Google Scholar
• JonesPHDavidsonMHReporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statinAm J Cardiol200595112012215619408
   PubMed Web of Science ®Google Scholar
• KamannaVSGanjiSHKashyapMLRecent advances in niacin and lipid metabolismCurr Opin Lipidol201324323924523619367
   PubMed Web of Science ®Google Scholar
• BaysHEBallantyneCWhat’s the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?Curr Opin Lipidol200920646747619779335
   PubMed Web of Science ®Google Scholar
• AIM-HIGH InvestigatorsBodenWEProbstfieldJLNiacin in patients with low HDL cholesterol levels receiving intensive statin therapyN Engl J Med2011365242255226722085343
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme CorpMerck Announces HPS2-THRIVE Study of TREDAPTIVE™ (Extended-Release Niacin/Laropiprant) Did Not Achieve Primary Endpoint [press release]Whitehouse Station, NJMerck Sharp & Dohme Corp20121220 Available from: http://www.mercknewsroom.com/press-release/prescription-medicine-news/merck-announces-hps2-thrive-study-tredaptive-extended-relea#sthash.8dgN5z3w.dpufAccessed June 6, 2014
   Google Scholar
• ElamMBHunninghakeDBDavisKBEffect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention TrialJAMA2000284101263127010979113
   PubMed Web of Science ®Google Scholar
• GrundySMVegaGLMcGovernMEDiabetes Multicenter Research GroupEfficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trialArch Intern Med2002162141568157612123399
   PubMedGoogle Scholar
• GuytonJRBaysHESafety considerations with niacin therapyAm J Cardiol2007996A22C31C
   PubMed Web of Science ®Google Scholar
• MacLeanAMcKenneyJScottREfficacy and safety of extended-release niacin/laropiprant in patients with type 2 diabetes mellitusBr J Cardiol2011183745
   Google Scholar
• BaysHENeffDTomassiniJETershakovecAMEzetimibe: cholesterol lowering and beyondExpert Rev Cardiovasc Ther20086444747018402536
   PubMedGoogle Scholar
• DenkeMPearsonTMcBridePGazzaraRABradyWETershakovecAMEzetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndromeDiabetes Vasc Dis Res20063293102
   Google Scholar
• GoldbergRBGuytonJRMazzoneTEzetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL studyMayo Clin Proc200681121579158817165637
   PubMed Web of Science ®Google Scholar
• SimonsLTonkonMMasanaLEffects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndromeCurr Med Res Opin20042091437144515383192
   PubMed Web of Science ®Google Scholar
• BardiniGGiordaCBPontiroliAELe GrazieCRotellaCMEzetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study)Cardiovasc Diabetol201092020492655
   PubMed Web of Science ®Google Scholar
• GaudianiLMLewinAMeneghiniLEfficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patientsDiabetes Obes Metab200571889715642080
   PubMed Web of Science ®Google Scholar
• ConardSBaysHLeiterLAEzetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neitherDiabetes Obes Metab201012321021820151997
   PubMed Web of Science ®Google Scholar
• Vytorin^® [prescribing information]Whitehouse Station, NJMerck Sharp and Dohme Corp, a subsidiary of Merck & Co Inc2014
   Google Scholar
• CannonCPGiuglianoRPBlazingMAIMPROVE-IT InvestigatorsRationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromesAm Heart J2008156582683219061694
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme CorpIMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103 AM5) Available from: http://clinicaltrials.gov/show/NCT00202878Accessed January 12, 2014 NLM identifier: NCT00202878
   Google Scholar
• BeysenCMurphyEJDeinesKEffect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled studyDiabetologia201255243244222134839
   PubMed Web of Science ®Google Scholar
• SmushkinGSathananthanMPiccininiFThe effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetesDiabetes20136241094110123250357
   PubMed Web of Science ®Google Scholar
• SuzukiTObaKIgariYColestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7–36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemiaJ Nippon Med Sch200774533834317965527
   PubMedGoogle Scholar
• BaysHDujovneCColesevelam HCl: a non-systemic lipid-altering drugExpert Opin Pharmacother20034577979012740000
   PubMed Web of Science ®Google Scholar